Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KPTI Karyopharm Therapeutics Inc.

交易中 09-14 09:48:44 EDT

1.60

-0.01

-0.62%

最高1.60	最低1.55	成交量8.17万
今开1.55	昨收1.61	日振幅3.11%
总市值3,626万	流通市值2,524万	总股本2,266万
成交额12.76万	换手率0.52%	流通股本1,577万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KPTI","market":"US","secType":"STK","nameCN":"Karyopharm Therapeutics Inc.","latestPrice":1.6,"timestamp":1789393712058,"preClose":1.61,"halted":0,"volume":81684,"delay":0,"changeRate":-0.006211180124223607,"floatShares":15774200,"shares":22662943,"eps":-13.0816,"marketStatus":"交易中","change":-0.01,"latestTime":"09-14 09:48:44 EDT","open":1.55,"high":1.6,"low":1.55,"amount":127581.21855,"amplitude":0.031056,"askPrice":1.61,"askSize":802,"bidPrice":1.59,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-13.0816,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1383714000000,"exchange":"NASDAQ","adjPreClose":1.61,"preHourTrading":{"tag":"盘前","latestPrice":1.56,"preClose":1.61,"latestTime":"09:01 EDT","volume":18190,"amount":29107.157784,"timestamp":1789390906637,"change":-0.05,"changeRate":-0.031056,"amplitude":0.055901},"postHourTrading":{"tag":"盘后","latestPrice":1.6004,"preClose":1.61,"latestTime":"19:59 EDT","volume":18447,"amount":29668.5655,"timestamp":1789171190183,"change":-0.0096,"changeRate":-0.005963,"amplitude":0.018323},"volumeRatio":0.847121,"impliedVol":1.8961,"impliedVolPercentile":0.6255},"requestUrl":"/m/hq/s/KPTI/tweets","defaultTab":"tweets","newsList":[{"id":"1175519337","title":"Karyopharm Therapeutics 未按期支付2026年9月10日到期1580万美元本金分期款项——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1175519337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175519337?lang=zh_cn&edition=full","pubTime":"2026-09-11 19:48","pubTimestamp":1789127289,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics公司（纳斯达克代码：KPTI）在向美国证券交易委员会（SEC）提交的文件中揭示，其未能按时支付一笔到期应付的本金分期付款。\n据悉，这笔款项金额高达1580万美元，原定于2026年9月10日支付。该公司此次违约行为已引起市场关注，反映出其在债务履约方面面临的压力。\n文件显示，该笔未付本金分期款的到期日已过，但公司尚未履行相应的支付义务。这一财务动态凸显了Karyopharm Therapeutics当前流动性状况可能面临的挑战。\n市场参与者正在密切关注该公司后续的偿债计划及可能的应对措施，以评估这一事件对其财务健康状况和未来运营的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159399474","title":"Karyopharm Therapeutics向FDA提交Xpovio®（塞利尼索）联合Ruxolitinib治疗骨髓纤维化的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1159399474","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159399474?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:31","pubTimestamp":1788175873,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics宣布，已向美国食品药品监督管理局（FDA）提交了补充新药申请（sNDA），旨在寻求批准Xpovio®（塞利尼索，Selinexor）与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139049633","title":"Karyopharm Therapeutics 携手 Centerview Partners，积极评估融资与战略替代方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1139049633","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139049633?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:36","pubTimestamp":1786620969,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics 正与 Centerview Partners 紧密合作，主动审视融资机会并探索各类战略替代方案。这一举措表明，这家生物制药公司正在大胆寻求资金补充与业务转型的潜在路径，旨在应对当前市场环境的挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157957381","title":"Karyopharm Therapeutics：计划于8月提交Selinexor联合Ruxolitinib治疗骨髓纤维化的sNDA申请按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1157957381","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157957381?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:35","pubTimestamp":1786620958,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. 宣布，其计划于8月提交的补充新药申请（sNDA）正在按既定时间表稳步推进。该申请旨在寻求批准Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化患者。这一进展标志着公司在关键临床试验成果转化道路上迈出了坚实的一步，为期待新疗法的病患群体带来了潜在希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173189756","title":"Karyopharm 公布2026年第二季度财务业绩，并强调骨髓纤维化sNDA申报工作持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1173189756","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173189756?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:32","pubTimestamp":1786620777,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. 近日披露了2026年第二季度的财务数据，同时对外释放出明确信号——其针对骨髓纤维化的补充新药申请（sNDA）准备工作正稳步向前推进。这一进展，无疑为市场注入了新的关注焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199634645","title":"Karyopharm Therapeutics 申请优先审评：Selinexor联合Ruxolitinib提交补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1199634645","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199634645?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:30","pubTimestamp":1785443409,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics 宣布，将寻求优先审评资格，针对其药物 Selinexor 与 Ruxolitinib 联合使用的方案，提交补充新药申请（sNDA）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127835746","title":"Karyopharm计划提交Selinexor联合Ruxolitinib治疗骨髓纤维化的加速审批补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1127835746","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127835746?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:29","pubTimestamp":1785443394,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.（KPTI）近日宣布，公司计划提交一项补充新药申请（sNDA），旨在推动其核心药物组合——Selinexor与Ruxolitinib的联合疗法，用于治疗骨髓纤维化。这一申请将走加速审批通道，寻求监管机构的快速审查与批准。此举标志着Karyopharm在血液肿瘤领域迈出关键一步，尤其针对那些对现有治疗反应不佳的患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188494010","title":"Karyopharm公布2026年第一季度财务业绩并完成子宫内膜癌三期试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1188494010","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188494010?lang=zh_cn&edition=full","pubTime":"2026-05-14 19:31","pubTimestamp":1778758278,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. (KPTI) 近日宣布了其2026年第一季度的财务业绩，并同步披露了一项关键临床进展：公司已成功完成其针对子宫内膜癌的三期临床试验的患者招募工作。\n这一进展标志着公司核心管线药物selinexor在拓展新适应症方面迈出了重要一步。子宫内膜癌是女性生殖系统常见的恶性肿瘤，此次三期试验的顺利完成，为后续获取关键疗效数据、寻求监管批准奠定了坚实基础。\n与此同时，公司公布的2026年第一季度财务数据，为投资者评估其当前运营状况与资金储备提供了最新依据。在推进多项后期临床研究的同时，公司的财务状况与研发里程碑共同构成了市场关注的核心焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196415628","title":"Karyopharm Therapeutics股价盘前飙升16%，其血癌药物在后期研究中达成两大主要目标之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1196415628","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196415628?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:36","pubTimestamp":1774352204,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.（股票代码：KPTI）股价在盘前交易中大幅上涨16%，此前该公司宣布其研发的一款血癌药物在一项关键后期研究中，成功达到了预设的两大主要目标之一。这一积极进展为药物的后续审批及商业化前景注入了强劲动力，显著提振了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116071082","title":"Karyopharm将与美国FDA会面 商讨Sentry试验数据及潜在sNDA申请事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1116071082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116071082?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:02","pubTimestamp":1774350132,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc. 即将与美国食品药品监督管理局（FDA）举行会议，重点讨论其Sentry临床试验所获得的数据结果，以及后续提交补充新药申请（sNDA）的潜在可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185126516","title":"Karyopharm骨髓纤维化三期Sentry试验达成首个共同主要终点，脾脏体积缩小呈现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1185126516","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185126516?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:01","pubTimestamp":1774350093,"startTime":"0","endTime":"0","summary":"Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）宣布，其针对骨髓纤维化患者的三期Sentry临床试验已成功达到首个共同主要终点。数据显示，接受治疗的患者在脾脏体积缩小方面取得统计学上的显著改善。\n该突破性进展为骨髓纤维化治疗领域带来新的希望，标志着Karyopharm在血液恶性肿瘤治疗研发中迈出关键一步。研究人员将继续评估试验的第二个共同主要终点——总症状评分改善情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518822073","title":"Karyopharm Therapeutics Inc.盘中异动 早盘股价大涨5.22%报7.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518822073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518822073?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:19","pubTimestamp":1741616363,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时19分，Karyopharm Therapeutics Inc.股票出现波动，股价快速上涨5.22%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221923abf30e51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221923abf30e51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KPTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517944041","title":"Karyopharm Therapeutics Inc.盘中异动 临近午盘大幅跳水5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944041","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517944041?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:43","pubTimestamp":1741193017,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时43分，Karyopharm Therapeutics Inc.股票出现异动，股价大幅跳水5.20%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.04%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004337989d6422&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306004337989d6422&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KPTI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658033","title":"Karyopharm Therapeutics Inc.盘中异动 快速下跌5.09%报7.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658033?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:53","pubTimestamp":1741017185,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时53分，Karyopharm Therapeutics Inc.股票出现异动，股价急速跳水5.09%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353069637c0fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032353069637c0fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KPTI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516335036","title":"Baird：维持Karyopharm Therapeutics(KPTI.US)评级，由优于大市调整至优于大市评级, 目标价由75.00美元调整至54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516335036","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516335036?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006293,"startTime":"0","endTime":"0","summary":"Baird：维持Karyopharm Therapeutics(KPTI.US)评级，由优于大市调整至优于大市评级, 目标价由75.00美元调整至54.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516371793","title":"Karyopharm Therapeutics Inc.盘中异动 临近午盘急速下挫5.15%报7.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516371793","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516371793?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:46","pubTimestamp":1740761178,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时46分，Karyopharm Therapeutics Inc.股票出现波动，股价大幅下跌5.15%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100461898969801&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030100461898969801&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387366","title":"Karyopharm Therapeutics Inc.盘中异动 早盘大幅上涨5.49%报10.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387366","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514387366?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:14","pubTimestamp":1740672884,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时14分，Karyopharm Therapeutics Inc.股票出现异动，股价快速上涨5.49%。截至发稿，该股报10.37美元/股，成交量10.3353万股，换手率1.23%，振幅9.36%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.57%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228001444a25693d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228001444a25693d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514859852","title":"Karyopharm Therapeutics Inc.盘中异动 股价大涨7.74%报9.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514859852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514859852?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:38","pubTimestamp":1740580689,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时38分，Karyopharm Therapeutics Inc.股票出现波动，股价大幅上涨7.74%。截至发稿，该股报9.23美元/股，成交量1.793万股，换手率0.21%，振幅6.07%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.57%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262238099631506b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262238099631506b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KPTI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514893832","title":"HC Wainwright & Co.：维持Karyopharm Therapeutics(KPTI.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至56.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514893832","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514893832?lang=zh_cn&edition=full","pubTime":"2025-02-26 20:41","pubTimestamp":1740573703,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Karyopharm Therapeutics(KPTI.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至56.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26204148411567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KPTI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013593","title":"Karyopharm Therapeutics Inc.盘中异动 早盘股价大跌5.58%报0.562美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013593","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514013593?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:51","pubTimestamp":1740495082,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时51分，Karyopharm Therapeutics Inc.股票出现波动，股价急速下跌5.58%。截至发稿，该股报0.562美元/股，成交量9.8686万股，换手率0.08%，振幅5.90%。Karyopharm Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.06%。Karyopharm Therapeutics Inc.公司简介：Karyopharm Therapeutics Inc 是一家商业阶段的制药公司，开创了新型癌症疗法，致力于发现、开发和商业化针对核输出的药物，以治疗癌症和其他疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522512498925166&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522512498925166&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","KPTI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.karyopharm.com","stockEarnings":[{"period":"1week","weight":-0.1006},{"period":"1month","weight":-0.2069},{"period":"3month","weight":-0.8305},{"period":"6month","weight":-0.7949},{"period":"1year","weight":-0.7575},{"period":"ytd","weight":-0.7813}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Karyopharm Therapeutics Inc.于2008年12月22日在特拉华州注册成立。该公司是一家临床阶段的制药公司，专注于发现和开发针对核转运靶点的新型一线药物，用于治疗癌症和重大疾病。该公司的科学专长集中在了解细胞核和细胞质之间细胞内运输的调节。","yearOnYearQuotes":[{"month":1,"riseRate":0.307692,"avgChangeRate":-0.016},{"month":2,"riseRate":0.615385,"avgChangeRate":0.053911},{"month":3,"riseRate":0.538462,"avgChangeRate":0.020586},{"month":4,"riseRate":0.307692,"avgChangeRate":0.010096},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.032894},{"month":6,"riseRate":0.615385,"avgChangeRate":0.016765},{"month":7,"riseRate":0.384615,"avgChangeRate":-0.086784},{"month":8,"riseRate":0.538462,"avgChangeRate":0.053113},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.031733},{"month":10,"riseRate":0.416667,"avgChangeRate":-0.041145},{"month":11,"riseRate":0.666667,"avgChangeRate":0.126143},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.06783}],"exchange":"NASDAQ","name":"Karyopharm Therapeutics Inc.","nameEN":"Karyopharm Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Karyopharm Therapeutics Inc.(KPTI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Karyopharm Therapeutics Inc.,KPTI,Karyopharm Therapeutics Inc.股票,Karyopharm Therapeutics Inc.股票老虎,Karyopharm Therapeutics Inc.股票老虎国际,Karyopharm Therapeutics Inc.行情,Karyopharm Therapeutics Inc.股票行情,Karyopharm Therapeutics Inc.股价,Karyopharm Therapeutics Inc.股市,Karyopharm Therapeutics Inc.股票价格,Karyopharm Therapeutics Inc.股票交易,Karyopharm Therapeutics Inc.股票购买,Karyopharm Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Karyopharm Therapeutics Inc.(KPTI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Karyopharm Therapeutics Inc.(KPTI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}